

## Clinical Trials Study

**PIK3CA gene mutations in Northwest Chinese esophageal squamous cell carcinoma**

Shi-Yuan Liu, Wei Chen, Ehtesham Annait Chughtai, Zhe Qiao, Jian-Tao Jiang, Shao-Min Li, Wei Zhang, Jin Zhang

Shi-Yuan Liu, Zhe Qiao, Jian-Tao Jiang, Shao-Min Li, Wei Zhang, Jin Zhang, Department of Thoracic Surgery, Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710004, Shaanxi Province, China

Wei Chen, Department of Medical Biochemistry and Molecular Biology, School of Basic Medical Sciences, Lanzhou University, Lanzhou 730000, Gansu Province, China

Ehtesham Annait Chughtai, Xi'an Jiaotong University School of Medicine, Xi'an 710061, Shaanxi Province, China

**Author contributions:** Liu SY, Chen W and Zhang J designed the research; Qiao Z, Jiang JT, Li SM and Zhang W performed the research; Liu SY and Chughtai EA analyzed data; Liu SY and Chughtai EA wrote the paper.

**Supported by National Natural Science Foundation of China,** No. 81602023.

**Institutional review board statement:** Written consent was obtained from each subject and the study procedures were approved by the ethical committees of the Second Affiliated Hospital of Xi'an Jiaotong University.

**Informed consent statement:** All study participants, or their legal guardian, provided informed written consent prior to study enrollment.

**Conflict-of-interest statement:** The authors declare no conflicts of interest.

**Data sharing statement:** No additional data are available.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

**Manuscript source:** Unsolicited manuscript

**Correspondence to:** Dr. Jin Zhang, Department of Thoracic Surgery, Second Affiliated Hospital of Xi'an Jiaotong University, No. 157 Xi Wu Lu, Xi'an 710004, Shaanxi Province, China. [mansteinxjtu@163.com](mailto:mansteinxjtu@163.com)  
Telephone: +86-29-87679325

**Received:** December 30, 2016

**Peer-review started:** January 1, 2017

**First decision:** February 9, 2017

**Revised:** February 19, 2017

**Accepted:** March 2, 2017

**Article in press:** March 2, 2017

**Published online:** April 14, 2017

## Abstract

### AIM

To evaluate *PIK3CA* gene mutational status in Northwest Chinese esophageal squamous cell carcinoma (ESCC) patients, and examine the associations of *PIK3CA* gene mutations with clinicopathological characteristics and clinical outcome.

### METHODS

A total of 210 patients with ESCC who underwent curative resection were enrolled in this study. Pyrosequencing was applied to investigate mutations in exons 9 and 20 of *PIK3CA* gene in 210 Northwest Chinese ESCCs. The associations of *PIK3CA* gene mutations with clinicopathological characteristics and clinical outcome were examined.

### RESULTS

*PIK3CA* gene mutations in exon 9 were detected in 48 cases (22.9%) of a non-biased database of 210 curatively resected Northwest Chinese ESCCs. *PIK3CA* gene mutations were not associated with sex, tobacco

use, alcohol use, tumor location, stage, or local recurrence. When compared with wild-type *PIK3CA* gene cases, patients with *PIK3CA* gene mutations in exons 9 experienced significantly better disease-free survival and overall survival rates.

### CONCLUSION

The results of this study suggest that *PIK3CA* gene mutations could act as a prognostic biomarker in Northwest Chinese ESCC patients.

**Key words:** *PIK3CA* gene mutations; Esophageal squamous cell carcinoma; Northwest Chinese; Prognostic significance

© **The Author(s) 2017.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** *PIK3CA* gene mutations have been associated with various prognoses in patients with different cancers. However, no large-scale study has examined the prognostic impact of *PIK3CA* gene mutations in Northwest Chinese esophageal squamous cell carcinoma (ESCC). In this study, we quantified *PIK3CA* gene mutations *via* pyrosequencing technology using a non-biased database of 210 curatively resected ESCCs. It was found that *PIK3CA* gene mutations in Northwest Chinese ESCC are associated with favorable prognoses. It has been suggested that *PIK3CA* gene mutational status can have a potential role as a prognostic biomarker for ESCC.

Liu SY, Chen W, Chughtai EA, Qiao Z, Jiang JT, Li SM, Zhang W, Zhang J. *PIK3CA* gene mutations in Northwest Chinese esophageal squamous cell carcinoma. *World J Gastroenterol* 2017; 23(14): 2585-2591 Available from: URL: <http://www.wjgnet.com/1007-9327/full/v23/i14/2585.htm> DOI: <http://dx.doi.org/10.3748/wjg.v23.i14.2585>

## INTRODUCTION

Esophageal squamous cell carcinoma (ESCC) is a major histologic type of esophageal cancer that is one of the most aggressive malignant tumors worldwide, especially in East Asian countries, and accounts for most esophageal malignancies in China and Japan<sup>[1,2]</sup>. As one of the most commonly diagnosed cancers among men in China, the estimated number of new cases of esophageal cancer was 291238 in 2011, while the numbers of deaths was 218957 in the same year<sup>[3]</sup>; by 2015, these numbers had increased to 477900 and 375000, respectively<sup>[4]</sup>. Both the incidence and mortality rates were higher in rural areas than in urban areas. Despite the continuing development of cancer multimodality therapies, including surgery, radiotherapy, and chemotherapy, the prognosis of ESCC patients remains poor, even for those who undergo complete resection of their carcinomas<sup>[5]</sup>.

Phosphatidylinositol 3-kinases (PI3Ks) are expressed as heterodimers of p110 catalytic subunits and p85 regulatory subunits that interact with phosphatidylinositol-3-phosphate at the membrane and catalyze the phosphorylation of protein kinase B (PKB, also known as AKT), which activates the downstream signaling pathway<sup>[6]</sup>. Activation of the PI3K/AKT signaling pathway plays an important role in the development of a variety of human carcinomas<sup>[7]</sup>. The catalytic subunits of PI3K are encoded by three genes ( $\alpha$ ,  $\beta$ ,  $\gamma$ ), with p110 $\alpha$  subunit (*PIK3CA*) amplification being reported in a number of different tumor types. The mutant *PIK3CA* gene stimulates the AKT pathway and promotes cell growth and invasion in various types of human cancer<sup>[8,9]</sup> (Samuels, 2004 #620; Samuels, 2005 #638), including lung, breast, gastric, and colon<sup>[10-17]</sup>.

*PIK3CA* gene mutations have also been detected in Japanese and Korean ESCCs<sup>[18,19]</sup>. Although independently associated with a poor prognosis in Chinese breast cancer patients<sup>[13]</sup>, it was found to be associated with improved outcome in breast cancer patients in the United States<sup>[20]</sup>; this seeming contradiction requires an intensive study of this gene in future research. In addition, *PIK3CA* gene mutations and their prognostic role in Chinese ESCC patients have been rarely reported. We therefore quantified *PIK3CA* gene mutations in 210 samples of curatively resected ESCCs using pyrosequencing, and examined the prognostic significance of *PIK3CA* gene mutations in Northwest Chinese ESCC patients.

## MATERIALS AND METHODS

### Study subjects

A total of 210 patients with ESCC who underwent curative resection at the Second Affiliated Hospital of Xi'an Jiaotong University between 2009 and 2015 were enrolled in this study. Patients were observed at 1 to 3 mo intervals until either death or December 30, 2015. Tumor staging was carried out according to the 7<sup>th</sup> American Joint Committee Cancer Staging Manual<sup>[21]</sup>. Disease-free survival was defined as the length of time after surgical treatment of the cancer during which the patient survived with no sign of cancer recurrence. Cancer-specific survival was defined as the time between the date of operation and the date of death, which was confirmed to be attributable to ESCC. Overall survival was defined as the time between the date of the operation and the date of death. Written consent was obtained from each subject and the study procedures were approved by the ethical committees of the Second Affiliated Hospital of Xi'an Jiaotong University.

### Genomic DNA extraction, polymerase chain reaction, and pyrosequencing of *PIK3CA* exon 9 and exon 20

Genomic DNA was extracted from 210 paraffin-embedded tissue specimens of surgically resected

**Table 1** Two sets of primers of exon 9 and 20 of *PIK3CA* gene for polymerase chain reaction

Exon	Primers	
Exon 9	Forward	5'CAAAGCAATTTCTACACGAGATCC 3'
	Reverse	5'GTAAAAACATGCTGAGATCAGCCACAT 3'
Exon 20	Forward	5'TGGAATGCCAGAACTACAATCTTT 3'
	Reverse	5'GGTCITTTGCTGCTGAGAGTT 3'

esophageal cancers using the QIAamp DNA Mini kit (Qiagen, Hilgen, Germany) according to the manufacturer's instructions.

Polymerase chain reaction (PCR) amplifications targeting the *PIK3CA* gene (exon 9 and 20) were performed. Two sets of primers (Table 1) were used for the detection of any mutation points in exons 9 and 20 of the *PIK3CA* gene. PCR was carried out in a total volume of 20  $\mu$ L. The mixture included 1x HotStarTaq buffer, 2.0 mmol/L  $Mg^{2+}$ , 0.2 mmol/L dNTP, 0.2  $\mu$ mol/L of each primer, 1U HotStarTaq polymerase (Qiagen, Hilgen, Germany), and 1  $\mu$ L template DNA. The cycling program for exon 9 was initial denaturation at 95  $^{\circ}$ C for 15 min, followed by 11 cycles at 94  $^{\circ}$ C for 20 s, 62  $^{\circ}$ C-0.5  $^{\circ}$ C per cycle for 40 s, and 72  $^{\circ}$ C for 1 min. The cycling program for exon 20 was initial denaturation at 95  $^{\circ}$ C for 15 min, followed by 27 cycles at 94  $^{\circ}$ C for 20 s, 56  $^{\circ}$ C for 30 s, and 72  $^{\circ}$ C for 1 min. The PCR products were electrophoresed on agarose gels to confirm successful amplification of the 81 (exon 9) and 74 bp (exon 20) products.

*PIK3CA* pyrosequencing was carried out using the Pyro-Mark Q24 System (Qiagen, Hilden, Germany) according to the manufacturer's instructions. Primers of *PIK3CA* gene (exon 9 and exon 20) for pyrosequencing are shown in Table 2.

### Statistical analysis

For the statistical analysis, we used GraphPad Prism 5 software (GraphPad Software, La Jolla, CA). The association between *PIK3CA* gene mutations and clinicopathological variables were performed using the  $\chi^2$ -test or Fisher's exact probability test. All *P* values were two-tailed, with a *P*-value less than 0.01 being considered significant. Estimation of overall survival was calculated using the Kaplan-Meier method, with statistical differences analyzed *via* the log-rank test.

## RESULTS

### *PIK3CA* gene mutational status in ESCC

For 210 patients who had undergone curative resection of stage I to III ESCC, we examined *PIK3CA* gene mutations (exon 9 and exon 20) by pyrosequencing technology. In this study, *PIK3CA* gene mutations were only observed in exon 9 in 48 (22.9%) of 210 Northwest Chinese ESCC samples. The most common mutation of *PIK3CA* exon 9 was the c.1634A>C (p.E545A) mutation, which was present in 35 tumors,

followed by c.1633G>A (p.E545K) in 13 tumors.

### *PIK3CA* gene mutations and ESCC patient characteristics

We examined whether the influence of *PIK3CA* gene mutations on cancer-specific survival was modified by any of the evaluated clinical, pathologic, or epidemiologic variables of the ESCCs. As a result, we found that *PIK3CA* gene mutations were not significantly associated with any of the evaluated characteristics of ESCCs, namely sex (male vs female), tobacco use (yes vs no), alcohol use (yes vs no), tumor location (upper, middle vs lower thoracic), preoperative treatment (yes vs no), lymph node metastasis (yes vs no), or local recurrence (yes vs no) (all *P* > 0.01; Table 3).

### *PIK3CA* gene mutations and patient survival

We assessed the influence of *PIK3CA* gene mutations on clinical outcome in Northwest Chinese patients with curatively resected ESCC. During the follow-up of the 210 patients, there were a total of 46 deaths confirmed to be attributable to esophageal cancer. The median follow-up time for censored patients was 36.5 mo. In the Kaplan-Meier analysis, patients with *PIK3CA* gene mutations experienced significantly longer disease-free survival (log rank *P* = 0.0094), cancer-specific survival (log rank *P* = 0.0059), and overall survival (log rank *P* = 0.0066) rates than those with the wild-type *PIK3CA* gene (Figure 1).

## DISCUSSION

Numerous genetic and functional studies have clearly established a fundamental role for the PI3K signaling pathway in the development of neoplasia. As an oncogene in various human cancers, *PIK3CA* is one of the most genetically mutated genes in human cancers (including colorectal, brain, and gastric cancers)<sup>[22]</sup>, having been displayed as mutated in various tumors, thereby making it a possible therapeutic marker. *PIK3CA* gene mutations and the subsequent activation of the PI3K/AKT pathway are considered to play a crucial role in cancer cell signaling pathways downstream of growth factors, cytokines, and other cellular stimuli in human neoplasm<sup>[6,23]</sup>. We therefore conducted this study to examine the prognostic impact of *PIK3CA* gene mutations among 210 Northwest Chinese patients with curatively resected ESCC.

In this study, we identified *PIK3CA* gene mutations in 48 out of 210 (22.9%) Northwest Chinese patients with curatively resected ESCC, which is a rate similar to that previously observed in ESCC (21%)<sup>[24]</sup>, colorectal cancer (32%)<sup>[9]</sup>, and breast cancer (25%-40%)<sup>[25,26]</sup>, but slightly higher than that for gastric cancers (4.3%)<sup>[27]</sup> and brain tumors (5%)<sup>[28]</sup>. Additionally, we also found that c.1634A>C (p.E545A) was the dominant mutation type, which was consistent with a previous study in China<sup>[29]</sup>. The *PIK3CA* gene mutation

**Table 2 Primers of *PIK3CA* gene for pyrosequencing**

Exon		Primers
Exon 9 RS1	Nucleotide dispensation order	5' CCATAGAAAATCTTTCTCCT 3'
Exon 9 RS2	Nucleotide dispensation order	5' ATCGACTACTGACTGACTGACTGACTGACTGACTG 3'
Exon 9 RS3	Nucleotide dispensation order	5' TTCTCCTTGCTTCAGTGATT 3'
Exon 20 RS	Nucleotide dispensation order	5' ATACACATGTCAGTCAGACTAGCTAGCTAGCTAG 3'
		5' TAGAAAATCTTTCTCCTGCT 3'
		5' ATAGCACTGACTGACTGACTGACTGACTGACTGACTG 3'
		5'TGGAATGCCAGAACTACAATCTTT 3'
		5'GGTCTTTGCCTGCTGAGAGTT 3'

**Table 3 *PIK3CA* mutations and clinicopathological characteristics in Northwest Chinese esophageal squamous cell carcinoma patients *n* (%)**

Clinical, epidemiologic, or pathologic feature	Total, <i>n</i>	<i>PIK3CA</i>		<i>P</i> value
		Mutant	Wild-type	
All cases	210	48	162	
Sex				0.4756
Male	137 (65.3)	34 (70.8)	123 (75.9)	
Female	73 (34.7)	14 (29.2)	39 (24.1)	
Tobacco use				0.2684
Yes	149 (71.0)	31 (64.6)	118 (72.9)	
No	61 (29.0)	17 (35.4)	44 (28.1)	
Alcohol use				0.3778
Yes	175 (83.3)	38 (79.2)	137 (84.6)	
No	35 (16.7)	10 (20.8)	25 (15.4)	
Preoperative treatment				0.8467
Yes	28 (13.3)	6 (12.5)	22 (13.6)	
No	182 (86.7)	42 (87.5)	140 (86.4)	
Tumor location				0.9651
Upper thoracic	20 (9.5)	5 (10.4)	15 (9.2)	
Middle thoracic	109 (51.9)	25 (52.1)	84 (51.9)	
Lower thoracic	81 (38.6)	18 (37.5)	63 (38.9)	
Stage				0.1641
I A	16 (7.6)	3 (6.3)	13 (8.0)	
I B	20 (9.5)	5 (10.4)	15 (9.3)	
II A	28 (13.3)	11 (22.9)	17 (10.5)	
II B	44 (21.0)	10 (20.8)	34 (21.0)	
III A	49 (23.3)	12 (25.0)	37 (22.8)	
III B	23 (11.0)	1 (2.1)	22 (13.6)	
III C	30 (14.3)	6 (12.5)	24 (14.8)	
Lymph node metastasis				0.2663
Yes	121 (57.6)	31 (64.6)	90 (55.6)	
No	89 (42.4)	17 (35.4)	72 (44.4)	
Local recurrence				0.7368
Yes	43 (20.5)	9 (18.8)	34 (21.0)	
No	167 (79.5)	39 (81.2)	128 (79.0)	
Prognosis				0.0885
Dead	88 (41.9)	15 (31.3)	73 (45.1)	
Survived	122 (58.1)	33 (68.7)	89 (54.9)	


frequency of ESCC in this study is slightly high when compared with those of previous studies; we believe this may be due to a difference in the patient cohorts, sample sizes, or methods used to assess *PIK3CA* gene mutation. When identifying *PIK3CA* gene mutations, other researchers typically use direct sequencing rather than the pyrosequencing used in the current study, which is a reliable high-throughput method that could be used as an alternative method for genotyping mutation studies<sup>[30]</sup>. There is also a non-electrophoretic nucleotide extension sequencing technology that can

be used for mutation detection in tumors. Additionally, pyrosequencing has been shown to be more sensitive than regular sequencing in detecting EGFR and KRAS mutations in lung cancer patients<sup>[31,32]</sup>. *PIK3CA* gene mutational status was not identified as being associated with any clinicopathological characteristics of Northwest Chinese ESCC patients in our study, which is consistent with two other studies in Korea and China<sup>[19,33]</sup>.

Identifying prognostic factors or biomarkers plays a crucial role in cancer research and clinical treatment<sup>[34-36]</sup>. Previous studies examining the relationship between *PIK3CA* gene mutations and prognosis in human cancers have yielded variable results and showed that *PIK3CA* gene mutational status is not associated with ESCC patient survival, although it does denote a better prognosis in breast cancer and ovarian cancer<sup>[37,38]</sup>. This discrepancy might be due to differences in tumor histologic type. We conducted this study to explore the prognostic impact of *PIK3CA* gene mutations among 210 Northwest Chinese patients with curatively resected ESCC. It was revealed that *PIK3CA* gene mutations were associated with a favorable prognosis among patients with curatively resected ESCC, suggesting *PIK3CA* gene mutational status may be a prognostic biomarker for Northwest Chinese ESCC patients that can be used to identify the clinical outcome of patients with curatively resected ESCC, which is consistent with its roles in Japanese ESCC patients<sup>[24]</sup>. Nonetheless, our findings regarding the correlation between *PIK3CA* mutations and favorable prognosis in esophageal cancer requires further confirmation by future independent studies using much larger non-biased cohorts of ESCCs.

In summary, this study suggests that *PIK3CA* gene mutations are associated with a favorable clinical outcome in operatively resected ESCC, which supports the *PIK3CA* gene's role as a prognostic biomarker for ESCC. Our data correlates with that of previous studies suggesting that the acquisition of *PIK3CA* gene mutations may be an important molecular event in the etiology of a wide range of tumor types and highlights the potential broad applicability that the *PIK3CA* gene may have in the clinical outcome of human cancers. Future studies are needed to confirm this association and clarify the exact molecular mechanisms by which *PIK3CA* gene mutations affects human cancer behavior.





**Figure 1** Kaplan-Meier curves for disease-free survival, cancer-specific survival, and overall survival in esophageal squamous cell carcinoma according to *PIK3CA* gene mutational status.

## COMMENTS

### Background

Esophageal squamous cell carcinoma (ESCC) is the predominant histological subtype of esophageal cancer in East Asian countries, where it accounts for more than 90% of total esophageal cancer cases. Despite the development of multimodality therapies, the prognosis of ESCC patients remains poor, even for those who undergo complete resection of their carcinomas. The 5-year survival rates of ESCC are between 11.1% and 56.5%, depending on the clinical stage at the time of diagnosis. With the development of high-throughput genome sequencing and screening technologies, an increasing number of cancer-associated genes have been identified to serve as potential therapeutic targets or prognostic indicators. High frequencies of somatic mutations conferring oncogenic potential have been found in the *PIK3CA* gene, which is associated with poor prognosis in patients with colorectal or lung cancer. In contrast, a relationship between *PIK3CA* gene mutations and favorable prognoses has been shown in breast cancer. However, no large-scale study has examined

the prognostic impact of *PIK3CA* gene mutations in Northwest Chinese ESCC patients.

### Research frontiers

The frequency of *PIK3CA* gene mutation in ESCC varied from 0% to 21%, which could likely introduce some bias in the statistical analyses of their clinical significance. More than 80% of *PIK3CA* gene mutations detected were localized in exons 9 and 20 (helical and kinase domain), with three “hot-spot” mutations: E542K, E545K, and H1047R. A recent report correlated with previous studies suggesting that the acquisition of *PIK3CA* mutations may be an important molecular event in the etiology of ESCC, and that mutations are associated with their clinical outcome.

### Innovations and breakthroughs

This is, by far, one of the largest studies on the prognostic role of *PIK3CA* gene mutations in Northwest Chinese ESCC to date, and it shows that *PIK3CA* gene mutations in ESCC are associated with a favorable prognosis. It has been suggested that *PIK3CA* gene mutational status can have a potential role as a prognostic biomarker for ESCC patients.

### Applications

*PIK3CA* gene mutations are associated with a favorable clinical outcome in operational resected Northwest Chinese ESCC patients, thereby suggesting that the acquisition of *PIK3CA* gene mutations may be an important molecular event in the etiology of a wide range of tumor types and highlighting the potential broad applicability that *PIK3CA* gene may have in the clinical outcome of human cancers.

### Terminology

The *PIK3CA* gene is located on the 3q26.3 chromosome and encodes the catalytic p110 alpha subunit of phosphoinositide 3-kinase (PI3K). The PI3K signaling pathway is deregulated in many types of cancer, with only the *PIK3CA* gene being reported as mutated and amplified.

### Peer-review

The authors examined the associations of *PIK3CA* gene mutations with clinicopathological characteristics and clinical outcome in esophageal squamous cell carcinoma patients in Northwest China. The authors exploited the most recent literature concerning the subject. The study suggests that *PIK3CA* gene mutations are associated with a favorable clinical outcome in esophageal squamous cell carcinoma and that in the future the evaluation of *PIK3CA* gene mutations may be potentially applied as a prognostic marker. The manuscript is worth sharing with other researchers. It is concise, clear, comprehensive, and convincing.

## REFERENCES

- 1 **Enzinger PC**, Mayer RJ. Esophageal cancer. *N Engl J Med* 2003; **349**: 2241-2252 [PMID: 14657432 DOI: 10.1056/NEJMra035010]
- 2 **Sasaki Y**, Tamura M, Koyama R, Nakagaki T, Adachi Y, Tokino T. Genomic characterization of esophageal squamous cell carcinoma: Insights from next-generation sequencing. *World J Gastroenterol* 2016; **22**: 2284-2293 [PMID: 26900290 DOI: 10.3748/wjg.v22.i7.2284]
- 3 **Zeng H**, Zheng R, Zhang S, Zuo T, Xia C, Zou X, Chen W. Esophageal cancer statistics in China, 2011: Estimates based on 177 cancer registries. *Thorax Cancer* 2016; **7**: 232-237 [PMID: 27042227 DOI: 10.1111/1759-7714.12322]
- 4 **Chen W**, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ, He J. Cancer statistics in China, 2015. *CA Cancer J Clin* 2016; **66**: 115-132 [PMID: 26808342 DOI: 10.3322/caac.21338]
- 5 **Gertler R**, Stein HJ, Langer R, Nettelmann M, Schuster T, Hoefler H, Siewert JR, Feith M. Long-term outcome of 2920 patients with cancers of the esophagus and esophagogastric junction: evaluation of the New Union Internationale Contre le Cancer/American Joint Cancer Committee staging system. *Ann Surg* 2011; **253**: 689-698 [PMID: 21475008 DOI: 10.1097/SLA.0b013e3182111b5]

- 6 **Manning BD**, Cantley LC. AKT/PKB signaling: navigating downstream. *Cell* 2007; **129**: 1261-1274 [PMID: 17604717 DOI: 10.1016/j.cell.2007.06.009]
- 7 **Engelman JA**, Luo J, Cantley LC. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. *Nat Rev Genet* 2006; **7**: 606-619 [PMID: 16847462 DOI: 10.1038/nrg1879]
- 8 **Samuels Y**, Diaz LA, Schmidt-Kittler O, Cummins JM, Delong L, Cheong I, Rago C, Huso DL, Lengauer C, Kinzler KW, Vogelstein B, Velculescu VE. Mutant PIK3CA promotes cell growth and invasion of human cancer cells. *Cancer Cell* 2005; **7**: 561-573 [PMID: 15950905 DOI: 10.1016/j.ccr.2005.05.014]
- 9 **Samuels Y**, Wang Z, Bardelli A, Silliman N, Ptak J, Szabo S, Yan H, Gazdar A, Powell SM, Riggins GJ, Willson JK, Markowitz S, Kinzler KW, Vogelstein B, Velculescu VE. High frequency of mutations of the PIK3CA gene in human cancers. *Science* 2004; **304**: 554 [PMID: 15016963 DOI: 10.1126/science.1096502]
- 10 **Nam SK**, Yun S, Koh J, Kwak Y, Seo AN, Park KU, Kim DW, Kang SB, Kim WH, Lee HS. BRAF, PIK3CA, and HER2 Oncogenic Alterations According to KRAS Mutation Status in Advanced Colorectal Cancers with Distant Metastasis. *PLoS One* 2016; **11**: e0151865 [PMID: 26991109 DOI: 10.1371/journal.pone.0151865]
- 11 **Jelovac D**, Beaver JA, Balukrishna S, Wong HY, Toro PV, Cimino-Mathews A, Argani P, Stearns V, Jacobs L, VanDenBerg D, Kessler J, Jeter S, Park BH, Wolff AC. A PIK3CA mutation detected in plasma from a patient with synchronous primary breast and lung cancers. *Hum Pathol* 2014; **45**: 880-883 [PMID: 24444464 DOI: 10.1016/j.humpath.2013.10.016]
- 12 **Whitehall VL**, Rickman C, Bond CE, Ramsnes I, Greco SA, Umapathy A, McKeone D, Faleiro RJ, Buttenshaw RL, Worthley DL, Nayler S, Zhao ZZ, Montgomery GW, Mallitt KA, Jass JR, Matsubara N, Notohara K, Ishii T, Leggett BA. Oncogenic PIK3CA mutations in colorectal cancers and polyps. *Int J Cancer* 2012; **131**: 813-820 [PMID: 21932420 DOI: 10.1002/ijc.26440]
- 13 **Lai YL**, Mau BL, Cheng WH, Chen HM, Chiu HH, Tzen CY. PIK3CA exon 20 mutation is independently associated with a poor prognosis in breast cancer patients. *Ann Surg Oncol* 2008; **15**: 1064-1069 [PMID: 18183466 DOI: 10.1245/s10434-007-9751-7]
- 14 **Abubaker J**, Bavi P, Al-Harbi S, Ibrahim M, Siraj AK, Al-Sanea N, Abduljabbar A, Ashari LH, Alhounoud S, Al-Dayel F, Uddin S, Al-Kuraya KS. Clinicopathological analysis of colorectal cancers with PIK3CA mutations in Middle Eastern population. *Oncogene* 2008; **27**: 3539-3545 [PMID: 18193083 DOI: 10.1038/sj.onc.1211013]
- 15 **Yamamoto H**, Shigematsu H, Nomura M, Lockwood WW, Sato M, Okumura N, Soh J, Suzuki M, Wistuba II, Fong KM, Lee H, Toyooka S, Date H, Lam WL, Minna JD, Gazdar AF. PIK3CA mutations and copy number gains in human lung cancers. *Cancer Res* 2008; **68**: 6913-6921 [PMID: 18757405 DOI: 10.1158/0008-5472.CAN-07-5084]
- 16 **Miyaki M**, Iijima T, Yamaguchi T, Takahashi K, Matsumoto H, Yasutome M, Funata N, Mori T. Mutations of the PIK3CA gene in hereditary colorectal cancers. *Int J Cancer* 2007; **121**: 1627-1630 [PMID: 17546593 DOI: 10.1002/ijc.22829]
- 17 **Fang WL**, Huang KH, Lan YT, Lin CH, Chang SC, Chen MH, Chao Y, Lin WC, Lo SS, Li AF, Wu CW, Chiou SH, Shyr YM. Mutations in PI3K/AKT pathway genes and amplifications of PIK3CA are associated with patterns of recurrence in gastric cancers. *Oncotarget* 2016; **7**: 6201-6220 [PMID: 26701847 DOI: 10.18632/oncotarget.6641]
- 18 **Mori R**, Ishiguro H, Kimura M, Mitsui A, Sasaki H, Tomoda K, Mori Y, Ogawa R, Katada T, Kawano O, Harada K, Fujii Y, Kuwabara Y. PIK3CA mutation status in Japanese esophageal squamous cell carcinoma. *J Surg Res* 2008; **145**: 320-326 [PMID: 18262558 DOI: 10.1016/j.jss.2007.03.044]
- 19 **Maeng CH**, Lee J, van Hummelen P, Park SH, Palescandolo E, Jiang J, Park HY, Kang SY, MacConaill L, Kim KM, Shim YM. High-throughput genotyping in metastatic esophageal squamous cell carcinoma identifies phosphoinositide-3-kinase and BRAF mutations. *PLoS One* 2012; **7**: e41655 [PMID: 22870241 DOI: 10.1371/journal.pone.0041655]
- 20 **Kalinsky K**, Jacks LM, Heguy A, Patil S, Drobnjak M, Bhanot UK, Hedvat CV, Traina TA, Solit D, Gerald W, Moynahan ME. PIK3CA mutation associates with improved outcome in breast cancer. *Clin Cancer Res* 2009; **15**: 5049-5059 [PMID: 19671852 DOI: 10.1158/1078-0432.CCR-09-0632]
- 21 **Rice TW**, Blackstone EH, Rusch VW. 7th edition of the AJCC Cancer Staging Manual: esophagus and esophagogastric junction. *Ann Surg Oncol* 2010; **17**: 1721-1724 [PMID: 20369299 DOI: 10.1245/s10434-010-1024-1]
- 22 **Murugan AK**, Munirajan AK, Tsuchida N. Genetic deregulation of the PIK3CA oncogene in oral cancer. *Cancer Lett* 2013; **338**: 193-203 [PMID: 23597702 DOI: 10.1016/j.canlet.2013.04.005]
- 23 **Samuels Y**, Velculescu VE. Oncogenic mutations of PIK3CA in human cancers. *Cell Cycle* 2004; **3**: 1221-1224 [PMID: 15467468 DOI: 10.4161/cc.3.10.1164]
- 24 **Shigaki H**, Baba Y, Watanabe M, Murata A, Ishimoto T, Iwatsuki M, Iwagami S, Noshio K, Baba H. PIK3CA mutation is associated with a favorable prognosis among patients with curatively resected esophageal squamous cell carcinoma. *Clin Cancer Res* 2013; **19**: 2451-2459 [PMID: 23532889 DOI: 10.1158/1078-0432.CCR-12-3559]
- 25 **Campbell IG**, Russell SE, Choong DY, Montgomery KG, Ciavarella ML, Hooi CS, Cristiano BE, Pearson RB, Phillips WA. Mutation of the PIK3CA gene in ovarian and breast cancer. *Cancer Res* 2004; **64**: 7678-7681 [PMID: 15520168 DOI: 10.1158/0008-5472.CAN-04-2933]
- 26 **Saal LH**, Holm K, Maurer M, Memeo L, Su T, Wang X, Yu JS, Malmström PO, Mansukhani M, Enoksson J, Hibshoosh H, Borg A, Parsons R. PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma. *Cancer Res* 2005; **65**: 2554-2559 [PMID: 15805248 DOI: 10.1158/0008-5472.CAN-04-3913]
- 27 **Li VS**, Wong CW, Chan TL, Chan AS, Zhao W, Chu KM, So S, Chen X, Yuen ST, Leung SY. Mutations of PIK3CA in gastric adenocarcinoma. *BMC Cancer* 2005; **5**: 29 [PMID: 15784156 DOI: 10.1186/1471-2407-5-29]
- 28 **Broderick DK**, Di C, Parrett TJ, Samuels YR, Cummins JM, McLendon RE, Fufts DW, Velculescu VE, Bigner DD, Yan H. Mutations of PIK3CA in anaplastic oligodendrogliomas, high-grade astrocytomas, and medulloblastomas. *Cancer Res* 2004; **64**: 5048-5050 [PMID: 15289301 DOI: 10.1158/0008-5472.CAN-04-1170]
- 29 **Wang L**, Shan L, Zhang S, Ying J, Xue L, Yuan Y, Xie Y, Lu N. PIK3CA gene mutations and overexpression: implications for prognostic biomarker and therapeutic target in Chinese esophageal squamous cell carcinoma. *PLoS One* 2014; **9**: e103021 [PMID: 25054828 DOI: 10.1371/journal.pone.0103021]
- 30 **Zhou Z**, Poe AC, Limor J, Grady KK, Goldman I, McCollum AM, Escalante AA, Barnwell JW, Udhayakumar V. Pyrosequencing, a high-throughput method for detecting single nucleotide polymorphisms in the dihydrofolate reductase and dihydropteroyl synthetase genes of *Plasmodium falciparum*. *J Clin Microbiol* 2006; **44**: 3900-3910 [PMID: 16957045 DOI: 10.1128/JCM.01209-06]
- 31 **Lee SE**, Lee SY, Park HK, Oh SY, Kim HJ, Lee KY, Kim WS. Detection of EGFR and KRAS Mutation by Pyrosequencing Analysis in Cytologic Samples of Non-Small Cell Lung Cancer. *J Korean Med Sci* 2016; **31**: 1224-1230 [PMID: 27478332 DOI: 10.3346/jkms.2016.31.8.1224]
- 32 **Xie G**, Xie F, Wu P, Yuan X, Ma Y, Xu Y, Li L, Xu L, Yang M, Shen L. The mutation rates of EGFR in non-small cell lung cancer and KRAS in colorectal cancer of Chinese patients as detected by pyrosequencing using a novel dispensation order. *J Exp Clin Cancer Res* 2015; **34**: 63 [PMID: 26081767 DOI: 10.1186/s13046-015-0179-9]
- 33 **Wang WF**, Xie Y, Zhou ZH, Qin ZH, Wu JC, He JK. PIK3CA hypomethylation plays a key role in activation of the PI3K/AKT pathway in esophageal cancer in Chinese patients. *Acta Pharmacol Sin* 2013; **34**: 1560-1567 [PMID: 24241346 DOI: 10.1038/

- aps.2013.163]
- 34 **Sutcliffe P**, Hummel S, Simpson E, Young T, Rees A, Wilkinson A, Hamdy F, Clarke N, Staffurth J. Use of classical and novel biomarkers as prognostic risk factors for localised prostate cancer: a systematic review. *Health Technol Assess* 2009; **13**: iii, xi-xiii 1-219 [PMID: 19128541 DOI: 10.3310/hta13050]
- 35 **Trapé J**, Montesinos J, Catot S, Buxó J, Franquesa J, Sala M, Domenech M, Sant F, Badal JM, Arnau A. A prognostic score based on clinical factors and biomarkers for advanced non-small cell lung cancer. *Int J Biol Markers* 2012; **27**: e257-e262 [PMID: 22815214 DOI: 10.5301/IJBM.2012.9314]
- 36 **Muc-Wierzgoń M**, Nowakowska-Zajdel E, Dzięgielewska-Gęsiak S, Kokot T, Klakla K, Fatyga E, Grochowska-Niedworok E, Waniczek D, Wierzgoń J. Specific metabolic biomarkers as risk and prognostic factors in colorectal cancer. *World J Gastroenterol* 2014; **20**: 9759-9774 [PMID: 25110413 DOI: 10.3748/wjg.v20.i29.9759]
- 37 **Barbareschi M**, Buttitta F, Felicioni L, Cotrupi S, Barassi F, Del Grammastro M, Ferro A, Dalla Palma P, Galligioni E, Marchetti A. Different prognostic roles of mutations in the helical and kinase domains of the *PIK3CA* gene in breast carcinomas. *Clin Cancer Res* 2007; **13**: 6064-6069 [PMID: 17947469 DOI: 10.1158/1078-0432.CCR-07-0266]
- 38 **Rahman M**, Nakayama K, Rahman MT, Nakayama N, Ishikawa M, Katagiri A, Iida K, Nakayama S, Otsuki Y, Shih IeM, Miyazaki K. Clinicopathologic and biological analysis of *PIK3CA* mutation in ovarian clear cell carcinoma. *Hum Pathol* 2012; **43**: 2197-2206 [PMID: 22705003 DOI: 10.1016/j.humpath.2012.03.011]

**P- Reviewer:** Ciesielski M, Ribas G **S- Editor:** Yu J  
**L- Editor:** Rutherford A **E- Editor:** Wang CH





Published by **Baishideng Publishing Group Inc**  
8226 Regency Drive, Pleasanton, CA 94588, USA  
Telephone: +1-925-223-8242  
Fax: +1-925-223-8243  
E-mail: [bpgoffice@wjgnet.com](mailto:bpgoffice@wjgnet.com)  
Help Desk: <http://www.f6publishing.com/helpdesk>  
<http://www.wjgnet.com>



ISSN 1007-9327

